| |
| |
|
| Insider
Information: |
Maraganore John |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
263,534 |
|
|
Indirect Shares
|
6,153,633 |
|
|
| Direct
Value |
$35,484,314 |
|
|
|
Indirect Value
|
$12,774,772 |
|
|
| Total
Shares |
6,417,167 |
|
|
| Total
Value |
$48,259,086 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alnylam Pharmaceuticals Inc |
ALNY |
Chief Executive Office... |
2021-12-22 |
227,663 |
2021-12-22 |
3,133 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Director, 10% Owner |
2012-10-10 |
0 |
2012-10-10 |
6,150,500 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2022-05-20 |
30,028 |
|
0 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
Director |
2017-09-14 |
5,843 |
2014-07-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
154 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • • |
2012-10-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,150,500 |
6,150,500 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2016-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
1,000 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
5,843 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
30 |
2,990 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2018-07-10 |
4 |
A |
$0.00 |
$0 |
I/I |
31 |
3,021 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2018-10-18 |
4 |
A |
$0.00 |
$0 |
I/I |
17 |
3,038 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2019-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
61 |
3,099 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2019-07-11 |
4 |
A |
$0.00 |
$0 |
I/I |
34 |
3,133 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2020-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
204,160 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2021-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,166 |
211,755 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2021-04-19 |
4 |
A |
$0.00 |
$0 |
D/D |
16,236 |
222,272 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2021-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
234,299 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-10-11 |
4 |
AB |
$6.75 |
$9,989 |
D/D |
1,480 |
48,980 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-11-14 |
4 |
AB |
$7.08 |
$9,997 |
D/D |
1,411 |
50,391 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2011-12-12 |
4 |
AB |
$7.15 |
$9,995 |
D/D |
1,397 |
51,788 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2012-01-09 |
4 |
AB |
$8.81 |
$9,995 |
D/D |
1,134 |
52,922 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President & CEO |
• • – |
2006-05-12 |
4 |
AS |
$14.94 |
$206,933 |
D/D |
(13,322) |
5,135 |
|
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
President & CEO |
• • – |
2006-05-12 |
4 |
AS |
$15.01 |
$428,070 |
D/D |
(28,313) |
18,457 |
|
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2007-06-28 |
4 |
AS |
$15.78 |
$320,253 |
D/D |
(20,069) |
17,431 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2007-06-28 |
4 |
AS |
$16.05 |
$280,262 |
D/D |
(17,431) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2007-06-29 |
4 |
AS |
$15.60 |
$269,298 |
D/D |
(17,089) |
1,689 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2007-06-29 |
4 |
AS |
$15.23 |
$287,605 |
D/D |
(18,722) |
18,778 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2007-06-29 |
4 |
AS |
$16.11 |
$27,371 |
D/D |
(1,689) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2008-08-13 |
4 |
AS |
$33.95 |
$1,273,005 |
D/D |
(37,500) |
0 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
CEO |
• • – |
2008-08-14 |
4 |
AS |
$34.23 |
$1,283,512 |
D/D |
(37,500) |
0 |
0 |
- |
|
154 Records found
|
|
Page 1 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
